|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1D-adrenoceptors in conductance arteries
Departamento de Farmacología, Facultad de Farmacia, Universitat de València, 46100 Burjassot, Valencia, Spain
| |
ABSTRACT |
|---|
|
|
|---|
A
constitutively active population of
1D-adrenoceptors in
iliac and proximal, distal, and small mesenteric rat arteries was studied. The increase in resting tone (IRT) that evidences it was
observed only in iliac and proximal mesenteric and was inhibited by
prazosin (pIC50 = 9.57), 5-methylurapidil
(pIC50 = 7.61), and BMY 7378 (pIC50 = 8.77). Chloroethylchlonidine (100 µmol/l) did not affect IRT, but
when added before the other antagonists it blocked their effect. The
potency shown by BMY 7378 confirms the
1D-subtype as
responsible for IRT. BMY 7378 displayed greater inhibition of
adrenergic responses in iliac (pIC50 = 7.57 ± 0.11) and proximal mesenteric arteries (pIC50 = 8.05 ± 0.2) than in distal (pIC50 = 6.94 ± 0.13) or small mesenteric arteries (pIC50 = 6.30 ± 0.14), which confirms the functional role of the
1D-adrenoceptor in iliac and proximal mesenteric
arteries. This subtype prevents abrupt changes in iliac and proximal
mesenteric artery caliber when the agonist disappears, and this
modulatory role is evidenced by the slower decay in the response to
norepinephrine after removal.
conductance vessels; resistance vessels; constitutive activity;
1D-adrenoceptors
| |
INTRODUCTION |
|---|
|
|
|---|
IT HAS BEEN CLEARLY
SHOWN that activation of
1-adrenoceptors mediates
vasoconstriction, and considerable progress has been made toward
elucidating the molecular structures and signal transduction mechanisms
of these adrenoceptors. Molecular cloning studies have identified three
1-adrenoceptor cDNAs (
1a,
1b, and
1d), and their primary structure
corresponds to the model of the superfamily of G protein-coupled
receptors. Moreover, three distinct
1-adrenoceptor subtypes (
1A,
1B, and
1D)
that correlate well with the cloned
1-adrenoceptors have
been identified pharmacologically in functional and binding experiments
(8, 9). These three subtypes display high, subnanomolar
affinities for prazosin. Furthermore, functional studies have provided
evidence of the existence of an additional
1L-adrenoceptor subtype displaying low affinity for
prazosin and some other
1-adrenoceptor antagonists
(3, 4, 23, 33). This
1L-adrenoceptor has no
molecular correlate. However, the physiological role of each
1-adrenoceptor in the vascular smooth muscle is unclear,
and the expression of an
1-adrenoceptor subtype in a
vessel is not always related to a functional role of this subtype in
the contractile tone of the vessel (10, 12, 16, 17, 29,
33).
In addition to the complex functionality of the different subtypes of
1-adrenoceptors, we have shown in previous studies (7, 24, 26) the existence of a population of
constitutively active
1D-adrenoceptors in the rat aorta
but not in the tail artery. The existence of this active conformation
has been revealed mainly in artificial models such as receptor mutants
or systems that show an overexpression of a certain type of receptor
(1, 13, 18, 19, 21, 31). However, until now, only our
studies in native tissues (7, 24, 26) and two recent
papers (5, 20) on cloned adrenoceptors have given new
evidence of the existence of a population of constitutively active
1D-adrenoceptors.
In our previous work, we suggested that this subtype, by remaining in
an active state when the agonist is removed, could be responsible for
the slower disappearance of the contractile response to the agonist in
the aorta than in the tail artery, but further studies in different
vessels are needed to confirm this hypothesis. The present report
analyzes the constitutive activity of
1D-adrenoceptors by examining its functional role in the contractile tone of different rat vessels, including conductance and resistance arteries, to glean
more information on the physiological implications of the constitutive
activity of
1D-adrenoceptors in the functionality of the
cardiovascular system.
| |
METHODS |
|---|
|
|
|---|
Rings of the aorta, iliac artery, and proximal or distal (with respect to the aorta) mesenteric arteries (~3-5 mm in length) of female Wistar rats (200-220 g) were denuded of the endothelium by gentle rubbing and suspended in a 10-ml organ bath containing physiological solution maintained at 37°C and gassed with 95% O2-5% CO2. An initial load of 1 g was applied to each preparation and maintained throughout a 75- to 90-min equilibration period. After this time, contractile responses to agonists were elicited according to the experimental procedures described in Experimental Design. The pretension of 1 g was kept constant, but there was a loss of tension (<10-15%) when the preparations were placed in Ca2+-free medium. Tension was recorded isometrically by Grass FTO3 force-displacement transducers, and data were recorded on a disc (MacLab).
Mesenteric arterial trees were dissected and cleared of surrounding adipose tissue. As described previously (22), a ring segment (2 mm in length) from the second branch of the arterial tree was mounted in a myograph (J. P. Trading; Aarhus, Denmark) with 6-ml organ baths containing physiological solution at 37°C and was gassed with 95% O2-5% CO2. After a 30-min stabilization period, the internal diameter of each vessel was set to a tension equivalent to 0.9 times the estimated diameter at 100 mmHg of effective transmural pressure (l100 = 90-180 µm) according to the standard procedure of Ref. 22. Tension was recorded isometrically, and data were recorded on a disk (MacLab).
The absence of relaxant response (>10%) after acetylcholine (10 µmol/l) addition to preparations precontracted with noradrenaline (1 µmol/l) indicated the absence of a functional endothelium in all the rings.
Experimental Designs
Maximal response to
1-adrenoceptor agonists.
A single agonist curve was obtained by cumulative addition of several
concentrations of phenylephrine (1 nmol/l-100 µmol/l) or
norepinephrine (1 nmol/l-100 µmol/l) to determine the
concentration of each agonist needed to obtain the sustained maximal
contractile response in each tissue. This concentration was 10 µmol/l
in iliac and proximal and distal mesenteric arteries and 30 µmol/l in
small mesenteric arteries.
Experimental procedure that evidences the constitutive activity
of
1D-adrenoceptors.
Figure 1 shows the experimental procedure
designed to study the depletion of intracellular Ca2+
stores sensitive to norepinephrine in Ca2+-free medium and
the increase in resting tone (IRT) obtained in iliac and proximal
mesenteric arteries but not in distal or small mesenteric arteries by
subsequent exposure to Ca2+-containing solution during the
refilling of these stores.
|
Concentration-response curves of inhibition of the IRT to
selective
1-adrenoceptor antagonists.
In a separate series of experiments, the effects of prazosin (0.001 nmol/l-1 µmol/l), 5-methylurapidil (0.001 nmol/l-1
µmol/l), 8-[2-[4-(2-methoxyphenyl)-1-piperazynil]-8-azaspiro[4,5]decane-7,9-dione dihydrochloride (BMY 7378; 0.001 nmol/l-1 µmol/l), and
chloroethylclonidine (100 µmol/l) were assessed on IRT in the aorta,
iliac, and proximal mesenteric arteries. In this case, the experimental
procedure was similar to that shown in Fig. 1, but 10 min before and
during the second loading period in Ca2+-containing
solution for the refilling of internal Ca2+ stores
previously depleted by norepinephrine, a given concentration of each
antagonist was added. The magnitude of the second IRT (IRT2) in the
presence of each concentration of each compound was expressed as a
percentage of the reference IRT (IRT1) obtained in the absence of any
agent (see Fig. 1).
Concentration-response curves of relaxation to selective
1-adrenoceptor antagonists.
Concentration-response curves were performed by addition of cumulative
concentrations of prazosin (0.01 nmol/l-1 µmol/l), 5-methylurapidil (0.001 nmol/l-10 µmol/l), cyclazosin (0.001 nmol/l-1 µmol/l), and BMY 7378 (0.001 nmol/l-1 µmol/l) to
tissues in which sustained contractions had been induced by a maximal
concentration of phenylephrine (10 µmol/l) or norepinephrine (30 µmol/l). Relaxations were expressed as a percentage of the maximum
increment in tension obtained by agonist addition.
Analysis of Results
Contractions were expressed in millinewtons of developed tension or as a percentage of the agonist-induced contractions obtained in normal physiological solution. Increases in resting tone were also expressed as a percentage of the agonist-induced contraction in normal physiological solution.The concentration (
log [mol/l]) needed to produce 50% relaxation
or inhibition (pIC50) and the Hill slope of the curve
(nH) were obtained from a nonlinear regression
plot (GraphPad Software; San Diego, CA) from at least seven
concentrations. The results are presented as means ± SE;
n is the number of determinations obtained from different animals.
Chemicals
The following drugs were obtained from Sigma (St. Louis, MO): phenylephrine, l-norepinephrine, prazosin, and cyclazosin, and the following drugs were obtained from Research Biochemicals International (Natick, MA): BMY 7378, chlorethylclonidine and 5-methylurapidil. Other reagents were of analytic grade. All compounds were dissolved in distilled water.The composition of the physiological Ca2+-containing solution was (in mmol/l) 118 NaCl, 4.75 KCl, 1.8 CaCl2, 1.2 MgCl2, 1.2 KH2PO4, 25 NaHCO3, and 11 glucose. Ca2+-free solution had the same composition except that CaCl2 was omitted and EDTA (0.1 mmol/l) was added.
| |
RESULTS |
|---|
|
|
|---|
Figure 1 shows the experimental procedure designed to study the
depletion of intracellular Ca2+ stores sensitive to
norepinephrine and the IRT obtained by subsequent exposure to
Ca2+-containing physiological solution during the
refilling of these stores. Norepinephrine (10 µmol/l in iliac and
proximal or distal mesenteric arteries or 30 µmol/l in small
mesenteric arteries) evoked a sustained contraction, which was used to
monitor the maximal response obtained with this agonist in each
preparation. The magnitude of the maximal responses obtained in each
tissue are summarized in Table 1. After
the arteries were carefully washed, the return to the baseline was
slower in the iliac and proximal mesenteric arteries than in the distal
or small mesenteric arteries (Fig. 2).
Basal tone recovery in the iliac artery took 843 ± 79 s
(n = 11) and in the proximal mesenteric artery 545 ± 27 s (n = 5), whereas in the distal mesenteric
artery, basal tone was recuperated in only 279 ± 66 s
(n = 5) and in the small mesenteric arteries in
103 ± 16 s (n = 10).
|
|
We then changed to a Ca2+-free solution, and, after 20 min in this medium, the addition of norepinephrine (1, 10, or 30 µmol/l) also induced a small contraction (NE1 in Fig. 1), which was used as an index of the content of agonist-sensitive intracellular stores. No contraction or an insignificant contraction was evoked upon a second application of the agonist (NE2 in Fig. 1) in the same solution, which indicates depletion of internal Ca2+ stores sensitive to norepinephrine. After being carefully washed, each tissue was incubated for 20 min in Ca2+-containing solution to refill the intracellular Ca2+ stores, and a spontaneous IRT1 (see Fig. 1) was observed in the iliac and proximal mesenteric arteries but not in the distal or small mesenteric arteries (Table 1). The IRT observed was not sustained, and it decreased as slowly as the control response to norepinephrine in Ca2+-containing solution disappeared after washing, as Fig. 2 shows. Returning the tissues to a Ca2+-free solution and further application of norepinephrine (NE3) 20 min later reproduced the contractile response elicited first in Ca2+-free solution, which indicates a complete refilling of internal stores (Fig. 1). A new loading in Ca2+-containing solution gave a new IRT (IRT2) similar to the first one in the iliac and proximal mesenteric arteries (Fig. 1).
Concentration-response curves of inhibition to prazosin (0.001 nmol/l-1 µmol/l), BMY 7378 (0.001 nmol/l-1 µmol/l), and
5-methylurapidil (0.001 nmol/l-1 µmol/l) were obtained (Fig.
3) by adding concentrations of antagonist
10 min before and during the second loading period in
Ca2+-containing solution that permits the refilling of
internal Ca2+ stores previously depleted by norepinephrine
(IRT2). The magnitude of the IRT2 observed in the iliac artery during
this period in the presence of each concentration of antagonist was
expressed as a percentage of IRT1 obtained in the absence of any agent, and the calculated pIC50 and confidence limits were 9.93 (11.03-8.84) for prazosin (n = 5-7), 8.77 (9.36-7.64) for BMY 7378 (n = 6-7), and 7.61 (9.00-6.27) for 5-methylurapidil (n = 5-7).
The potency shown by BMY 7378 against the IRT relates this contraction
observed in the iliac artery to a population of constitutively active
1D-adrenoceptors, as has been shown in the rat aorta
(7, 26). When the concentration of BMY 7378 or prazosin
(0.1 µmol/l) that completely inhibits IRT2 in the aorta
(7) and iliac artery was assayed in the proximal mesenteric artery, the IRT2 was also completely inhibited, confirming that this response could also be related to a constitutively active population of
1D-adrenoceptors.
|
To confirm this hypothesis, chloroethylclonidine (100 µmol/l), which
failed to inhibit the IRT in the rat aorta (7), was used
as a neutral antagonist to see whether it could block the action of the
prazosin (1 µmol/l) and BMY 7378 (1 µmol/l) in the aorta and iliac
artery. As shown in Fig. 4, the previous
addition for 30 min of chloroethylclonidine (100 µmol/l), which
failed to inhibit the IRT observed in these tissues, clearly blocked the inhibitory effect of the other agents on IRT in the three vessels.
This concentration of chloroethylclonidine completely inhibits
norepinephrine-induced contraction in the aorta and iliac artery
(results not shown). In the proximal mesenteric artery we did not do
this, because chloroethylclonidine (100 µmol/l) itself induces a
contractile response that masks the IRT.
|
To corroborate the functional role of
1D-adrenoceptors
in the iliac and proximal mesenteric arteries and exclude their
participation in the distal and small mesenteric arteries,
concentration-response curves of relaxation to prazosin (0.01 nmol/l-1 µmol/l), BMY 7378 (0.001 nmol/l-1 µmol/l),
cyclazosin (0.001 nmol/l-1 µmol/l), and 5-methylurapidil (0.001 nmol/l-10 µmol/l) were obtained by adding cumulative
concentrations of the compounds to tissues in which sustained
contractions had been induced by a maximal concentration of agonist.
In the iliac and mesenteric arteries, where
2-adrenoceptors could have a functional role (2,
29), the
1-adrenoceptor-selective agonist
phenylephrine (10 µmol/l) was employed. Norepinephrine (30 µmol/l)
was used in the small mesenteric artery, where the contractile role of
2-adrenoceptors is excluded (28).
Relaxations were expressed as a percentage of the maximum increment in
tension obtained by agonist addition, and the potency
(pIC50) and nH of the fitted curves
of relaxation obtained for each antagonist in the different vessels are
summarized in Table 2.
|
In the iliac and proximal mesenteric arteries, the pIC50 of
BMY 7378 as a relaxant of phenylephrine-induced contraction suggests the participation of
1D-adrenoceptors together with
other subtypes (Table 2). The pIC50 shown by cyclazosin
does not exclude the participation of the
1B-subtype,
and the pIC50 and nH for
5-methylurapidil suggest a mixed population of
1-adrenoceptor subtypes. The results obtained in distal
and small mesenteric arteries are summarized in Table 2, but the lack
of potency of BMY 7378 excludes the functional role of the
1D-subtype in these tissues.
In small mesenteric arteries, the pIC50 obtained with
prazosin (8.48 ± 0.28; Table 2) was consistently lower than its
affinity reported for cloned
1A-,
1B-,
and
1D-subtypes (pKi = 9.9-10.4) (16, 32) and also lower than the
pIC50 obtained for prazosin in the iliac or proximal or
distal mesenteric arteries.
| |
DISCUSSION |
|---|
|
|
|---|
Previous results obtained in the rat aorta (7, 24,
26) show that, by activating
1-adrenoceptors,
norepinephrine releases Ca2+ from internal stores. When
emptied, the stores can be rapidly replenished by Ca2+
influx during the incubation in Ca2+-containing solution in
the absence of the agonist, and this process manifests itself not only
in the recovery of the response to norepinephrine in
Ca2+-free medium but also in the increased resting tone
(IRT in Fig. 1) and inositol trisphosphate accumulation observed
(7). As has been analyzed and discussed in
previous papers (7, 24, 26), endogenous or exogenous
agonists are not present; the fact that the IRT and the inositol
trisphosphate accumulation related to it were inhibited by prazosin and
BMY 7378, a selective antagonist of the
1D-subtype,
suggests the existence of a population of
1D-adrenoceptors that remains in a constitutively active
state, as we have previously proposed (7,
24-27). Moreover, the fact that this IRT was not
observed in the tail artery (7), where a population of
1A-adrenoceptors has been described (17),
suggests that this subtype does not show constitutive activity. Two
questions are brought up by these results: 1) whether this
is a general model for the
1D-subtype or depends on the
vascular smooth muscle in which the adrenoceptor is expressed, and
2) what the role of this process is in the functionality of
a given vessel.
To answer the first question, we analyzed this model in different rat
vascular tissues: iliac and proximal, distal, and small mesenteric
arteries. The experimental procedure was the same: after depletion of
internal Ca2+ stores sensitive to norepinephrine, an IRT
was observed (see Fig. 1) in the iliac and proximal mesenteric arteries
but not in the distal or small mesenteric arteries. The fact that the IRT observed can be selectively inhibited by BMY 7378 suggests the
existence of a population of
1D-adrenoceptors with
constitutive activity in these vessels, as we have previously shown in
the aorta (7). This affirmation is supported by the fact
that chloroethylclonidine, which acts as a neutral antagonist in the
rat aorta (7) and iliac artery (present results), can
block the action of the inverse agonists prazosin and BMY 7378 (see
Fig. 4) as well as the effect of the agonist norepinephrine.
These results suggest that, as occurs in the rat aorta (7,
26), the
1D-subtype shows constitutive activity
in the vessels in which it has a functional role. To confirm this role
in the iliac and proximal mesenteric arteries and exclude its
involvement in the functionality of the distal and small mesenteric
arteries, we assayed in these tissues the activity of different
selective antagonists: BMY 7378 and 5-methylurapidil, which show
selective affinity for the
1D- and
1A-subtypes, respectively, and cyclazosin, which shows
selective affinity for the
1B-subtype (6, 9, 32). The potency obtained by each selective antagonist
(pIC50) was interpreted as an indicator of the
functionality of a subtype in a given vessel.
The results obtained confirms that the population of
1-adrenoceptors that intervene in the functional
response of the iliac and proximal mesenteric artery to adrenergic
agonists belongs, at least in part, to the
1D-subtype. A
similar analysis in the distal mesenteric artery was performed, but the
potency of BMY 7378 was too low to account for
1D-adrenoceptor involvement in the response of this
vessel to adrenergic stimulus.
The present results are consistent with previous studies in the iliac
(29) and mesenteric arteries (12, 35) that
describe a role for the
1D-subtype in the functional
response of these vessels. However, the lack of a functional role for
the
1D-adrenoceptor in the distal mesenteric artery has
not been described previously and suggests that anatomic differences
related to proximity or distance with respect to the aorta could be
invoked to explain this discrepancy. According to the present results,
in the part of the mesenteric artery that is close to the aorta (the
proximal mesenteric artery), there remains a population of functionally active
1D-adrenoceptors, which, however, disappear
little by little as the artery moves away from the aorta and become
almost imperceptible in the section of the artery contiguous with the first branch of the mesenteric arterial tree (the distal mesenteric artery).
In the second branch of the small mesenteric arteries, the functionally
active
1-adrenoceptor subtypes display a peculiar pharmacology. The low pIC50 obtained for prazosin was more
consistent with the profile of the pharmacologically defined
1L-subtype (3, 4, 33, 34). However, other
reports propose that
1B-adrenoceptors mediate
contraction of small mesenteric arteries (30). Clearly,
then, in this tissue the exact role of the
1-adrenoceptor subtypes is still controversial. In any
case, the low potency of BMY 7378 excludes
1D-adrenoceptor participation in the functionality of
small mesenteric arteries, and, as occurs in the tail (7) or distal mesenteric arteries, the IRT was not observed either.
In conclusion, the functional role of the
1D-adrenoceptors, only revealed in the iliac and
proximal mesenteric arteries in the present study, implies the
existence, during a certain period of time, of a functional response in
the absence of the agonist that can be interpreted as the constitutive
activity of these receptors. This coincides with that occurring in the
rat aorta (7), a tissue in which the functionality of
1D-adrenoceptors is well defined (7, 12, 16,
23). In tissues such as the tail (7, 17), distal
mesenteric, or small mesenteric arteries, where
1D-adrenoceptors do not play a functional role, the
constitutive activity of a population of
1-adrenoceptors
is not observed. Therefore, this constitutive activity is only shown by
the
1D-adrenoceptor subtype and is observed in vessels
where this subtype has a functional role.
Interestingly, the same observation about the constitutive activity of
1D-adrenoceptors was recently reported by two different groups of researchers working with cloned
1D-adrenoceptors expressed in rat-1 fibroblasts
(5, 20)
The conclusion that only
1D-adrenoceptors exhibit
constitutive activity and that this constitutive activity can be
evidenced in different vessels when this subtype plays a functional
role answers the first question referred to above. But the data
gathered in the present study also clarify our second and more
interesting question about the physiological role of this constitutive
activity of
1D-adrenoceptors. Figures 1 and 2 show that
if we compare the norepinephrine-induced contractile responses in the
iliac artery and the different segments of mesenteric arteries in
Ca2+-containing solution, we can observe that, after the
agonist is removed, contraction disappears in the iliac and proximal
mesenteric arteries as slowly as IRT decreases, but that in distal and
small mesenteric arteries, the decay of the response to norepinephrine is faster. The same has been shown in the aorta, where
1D-adrenoceptors are present, compared with the tail
artery, where the functionality of this subtype is excluded
(7). From these results, we can extrapolate that in
physiological conditions, after norepinephrine activity and removal, a
population of
1D-adrenoceptors could remain in a
constitutively active state, temporarily coupled to G protein, and
could be responsible for the slow disappearance of the contractile
response to the agonist in a given vessel. This mechanism is not
observed in vessels where
1D-adrenoceptors do not seem
to play a functional role. Therefore, the presence of a population of
1D-adrenoceptors in a vessel signify that the
contractile responses of this tissue can be sustained even when the
agonist is removed, and this would in turn modulate the contractile
activity in this vessel, thus preventing abrupt changes in caliber when
the agonist disappears. According to our findings, in conductance
vessels like the aorta, proximal mesenteric, and iliac arteries,
1D-adrenoceptors play a modulatory role in the contractile tone and prevent sudden changes in blood flow. In contrast,
in the portion of distal or small mesenteric arteries that are farther
from the aorta, the lack of a functional role for
1D-adrenoceptors guarantees a fine, quick adjustment of
contractile tone and blood flow to the adrenergic stimulus.
We can extrapolate that an imbalance in this modulating mechanism could
give rise to pathologies such as hypertension or diabetes- or
age-related vascular diseases, in the pathogenesis and/or maintenance of which
1D-adrenoceptors could play a role, as has been
postulated by different authors (11, 14, 15, 35-37).
We are currently investigating this hypothesis, but the observations
reported here are the first to explain that the presence of different
1-adrenoceptor subtypes in a given vessel is due to the
fact that they are involved in different tissue functions.
| |
ACKNOWLEDGEMENTS |
|---|
This work was supported by Spanish Comisión Interministerial de Ciencia y Tecnología Research Grants SAF98-0123 and 1FD97-1029.
| |
FOOTNOTES |
|---|
Address for reprint requests and other correspondence: P. D'Ocon, Departamento de Farmacología, Facultad de Farmacia, Universitat de València, Avda. Vicent Andres Estelles s/n 46100 Burjassot, Valencia, Spain (E-mail: m.pilar.docon{at}uv.es).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
10.1152/ajpheart.00411.2001
Received 17 May 2001; accepted in final form 29 October 2001.
| |
REFERENCES |
|---|
|
|
|---|
1.
Bond, RA,
Leff P,
Johnson TD,
Milano CA,
Rockman HA,
McMinn TR,
Apparsundaram S,
Hyek MF,
Kenakin TP,
Allen LF,
and
Lefkovitz RJ.
Physiological effects of inverse agonists in transgenic mice with myocardial overexpression of the
2-adrenoceptor.
Nature
374:
272-276,
1995.
2.
Feres, T,
Borges AC,
Silva EG,
Paiva AC,
and
Paiva TB.
Impaired function of
2-adrenoceptors in smooth muscle of mesenteric arteries from spontaneously hypertensive rats.
Br J Pharmacol
125:
1144-1149,
1998.
3.
Flavahan, NA,
and
Vanhoutte PM.
1-Adrenoceptor subclassification in vascular smooth muscle.
Trends Pharmacol Sci
7:
347-349,
1986.
4.
Ford, APDW,
Williams TJ,
Blue DR,
and
Clarke DE.
Adrenoceptor calssification.
Trends Pharmacol Sci
15:
167-170,
1994.
5.
Garcia Sainz, JA,
and
Torres Padilla ME.
Modulation of basal intracellular calcium by inverse agonists and phorbol myristate acetate in rat-1 fibroblasts stably expressing
1d-adrenoceptors.
FEBS Lett
443:
277-281,
1999.
6.
Giardina, D,
Crucianelli M,
Melchiorre C,
Taddei C,
and
Testa R.
Receptor binding profile of cyclazosin, a new
1B-adrenoceptor antagonist.
Eur J Pharmacol
287:
13-16,
1995.
7.
Gisbert, R,
Noguera MA,
Ivorra MD,
and
D'Ocon P.
Functional role of a constitutively active population of
1D-adrenoceptors in rat vessels.
J Pharmacol Exp Ther
295:
810-817,
2000.
8.
Graham, RM,
Perez DM,
Hwa J,
and
Piascik MT.
1-Adrenergic receptor subtypes. Molecular structure, function, and signaling.
Circ Res
78:
737-749,
1996.
9.
Hieble, JP,
Bylund DB,
Clarke DE,
Eikenburg DC,
Langer SZ,
Lefkowitz RJ,
Minneman KP,
and
Ruffolo RR, Jr.
International Union of Pharmacology. X. Recommendation for nomenclature of
1-adrenoceptors: consensus update.
Pharmacol Rev
47:
267-270,
1995.
10.
Hrometz, SL,
Edelmann SE,
McCune DF,
Olges JR,
Hadley RW,
Perez DM,
and
Piascik MT.
Expression of multiple
1-adrenoceptors on vascular smooth muscle: correlation with the regulation of contraction.
J Pharmacol Exp Ther
290:
452-463,
1999.
11.
Hu, ZW,
Shi XY,
and
Hoffman B.
Insulin and insulin-like growth factor I differentially induce
1-adrenergic receptor subtype expression in rat vascular smooth muscle cells.
J Clin Invest
98:
1826-1834,
1996.
12.
Hussain, MB,
and
Marshall I.
Characterization of
1-adrenoceptor subtypes mediating contractions to phenylephrine in rat thoracic aorta, mesenteric artery and pulmonary artery.
Br J Pharmacol
122:
849-858,
1997.
13.
Hwa, J,
Gaivin R,
Porter JE,
and
Perez DM.
Synergism of constitutive activity in
1-adrenergic receptor activation.
Biochemistry
36:
633-639,
1997.
14.
Ibarra, M,
Lopez-Guerrero JJ,
and
Villalobos-Molina R.
Further evidence for the predominance of
1D-adrenoceptors in arteries of normotensive and spontaneously hypertensive rats.
Pharmacol Rev Comm
10:
135-142,
1998.
15.
Ibarra, M,
Terron JA,
Lopez-Guerrero JJ,
and
Villalobos-Molina R.
Evidence for an age-dependent functional expression of
1D-adrenoceptors in the rat vasculature.
Eur J Pharmacol
322:
221-224,
1997.
16.
Kenny, BA,
Chalmers DH,
Philpott PC,
and
Naylor AM.
Characterization of an
1D-adrenoceptor mediating the contractile response of rat aorta to noradrenaline.
Br J Pharmacol
115:
981-986,
1995.
17.
Lachnit, WG,
Tran AM,
Clarke DE,
and
Ford AP.
Pharmacological characterization of an
1A-adrenoceptor mediating contractile responses to noradrenaline in isolated caudal artery of rat.
Br J Pharmacol
120:
819-826,
1997.
18.
Lee, TW,
Cotecchia S,
and
Milligan G.
Up-regulation of the levels of expression and function of a constitutively active mutant of the hamster
1B-adrenoceptor by ligands that act as inverse agonists.
Biochem J
325:
733-739,
1997.
19.
Ligt, RAF,
Kourounakis AP,
and
Ijzerman AP.
Inverse agonism at G protein-coupled receptors: (patho)physiological relevance and implications for drug discovery.
Br J Pharmacol
130:
1-12,
2000.
20.
McCune, DF,
Edelmann SE,
Olges JR,
Post GR,
Waldrop BA,
Waugh DJJ,
Perez DM,
and
Piascik MT.
Regulation of the cellular localization and signaling properties of the
1B and
1D- adrenoceptors by agonists and inverse agonists.
Mol Pharmacol
57:
659-666,
2000.
21.
Mhaouty-Kodja, S,
Barak LS,
Scheer A,
Abuin L,
Diviani D,
Caron MG,
and
Cotecchia S.
Constitutively active
1B-adrenergic receptor mutants display different phosphorylation and internalization features.
Mol Pharmacol
55:
339-347,
1999.
22.
Mulvany, MJ,
and
Halpern W.
Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats.
Circ Res
41:
19-26,
1977.
23.
Muramatsu, I,
Murata S,
Isaka M,
Piao HL,
Zhu J,
Suzuki F,
Miyamoto S,
Oshita M,
Watanabe Y,
and
Taniguchi T.
1-Adrenoceptor subtypes and two receptor systems in vascular tissues.
Life Sci
62:
1461-1465,
1998.
24.
Noguera, MA,
and
D'Ocon MP.
Evidence that depletion of internal calcium stores sensitive to noradrenaline elicits a contractile response dependent on extracellular calcium in rat aorta.
Br J Pharmacol
110:
861-867,
1993.
25.
Noguera, MA,
Ivorra MD,
Chulia S,
and
D'Ocon P.
Capacitative Ca2+ entry associated with
1-adrenoceptors in rat aorta.
Naunyn Schmiedebergs Arch Pharmacol
356:
83-89,
1997.
26.
Noguera, MA,
Ivorra MD,
and
D'Ocon P.
Functional evidence of inverse agonism in vascular smooth muscle.
Br J Pharmacol
119:
158-164,
1996.
27.
Noguera, MA,
Madrero Y,
Ivorra MD,
and
D'Ocon P.
Characterization of two different Ca2+ entry pathways dependent on depletion of internal Ca2+ pools in rat aorta.
Naunyn Schmiedebergs Arch Pharmacol
357:
92-99,
1998.
28.
Phillips, JK,
McLean AJ,
and
Hill CE.
Receptors involved in nerve-mediated vasoconstriction in small arteries of the rat hepatic mesentery.
Br J Pharmacol
124:
1403-1412,
1998.
29.
Piascik, MT,
Guarino RD,
Smith MS,
Soltis EE,
Saussy DL, Jr,
and
Perez DM.
The specific contribution of the novel
1D-adrenoceptor to the contraction of vascular smooth muscle.
J Pharmacol Exp Ther
275:
1583-1589,
1995.
30.
Piascik, MT,
Hrometz SL,
Edelmann SE,
Guarino RD,
Hadley RW,
and
Brown RD.
Immunocytochemical localization of the
1B-adrenergic receptor and the contribution of this and the other subtypes to vascular smooth muscle contraction: analysis with selective ligands and antisense oligonucleotides.
J Pharmacol Exp Ther
283:
854-868,
1997.
31.
Rossier, O,
Abuin L,
Fanelli F,
Leonardi A,
and
Cotecchia S.
Inverse agonism and neutral antagonism at
1A- and
1B-adrenergic receptor subtypes.
Mol Pharmacol
56:
858-866,
1999.
32.
Schwinn, DA,
Johnston GI,
Page SO,
Mosley MJ,
Wilson KH,
Worman NP,
Campbell S,
Fidock MD,
Furness LM,
and
Parry-Smith DJ.
Cloning and pharmacological characterization of human
1-adrenergic receptors: sequence corrections and direct comparison with other species homologues.
J Pharmacol Exp Ther
272:
134-142,
1995.
33.
Stam, WB,
Van der Graaf PH,
and
Saxena PR.
Analysis of
1L-adrenoceptor pharmacology in rat small mesenteric artery.
Br J Pharmacol
127:
661-670,
1999.
34.
Van der Graaf, PH,
Shankley NP,
and
Black JW.
Analysis of the effects of
1-adrenoceptor antagonists on noradrenaline-mediated contraction of rat small mesenteric artery.
Br J Pharmacol
118:
1308-1316,
1996.
35.
Villalobos-Molina, R,
and
Ibarra M.
1-Adrenoceptors mediating contraction in arteries of normotensive and spontaneously hypertensive rats are of the
1D or
1A subtypes.
Eur J Pharmacol
298:
257-263,
1996.
36.
Villalobos-Molina, R,
Lopez-Guerrero JJ,
and
Ibarra M.
Functional evidence of
1D-adrenoceptors in the vasculature of young and adult spontaneously hypertensive rats.
Br J Pharmacol
126:
1534-1536,
1999.
37.
Xu, K,
Lu Z,
Wei H,
Zhang Y,
and
Han C.
Alteration of
1-adrenoceptor subtypes in aortas of 12-month-old spontaneously hypertensive rats.
Eur J Pharmacol
344:
31-36,
1998.
This article has been cited by other articles:
![]() |
E. Oliver, D. Marti, F. Monto, N. Flacco, L. Moreno, D. Barettino, M. D. Ivorra, and P. D'Ocon The Impact of {alpha}1-Adrenoceptors Up-Regulation Accompanied by the Impairment of {beta}-Adrenergic Vasodilatation in Hypertension J. Pharmacol. Exp. Ther., March 1, 2009; 328(3): 982 - 990. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Vinci, L. Bellik, S. Filippi, F. Ledda, and A. Parenti Trophic effects induced by {alpha}1D-adrenoceptors on endothelial cells are potentiated by hypoxia Am J Physiol Heart Circ Physiol, October 1, 2007; 293(4): H2140 - H2147. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Marti, R. Miquel, K. Ziani, R. Gisbert, M. D. Ivorra, E. Anselmi, L. Moreno, V. Villagrasa, D. Barettino, and P. D'Ocon Correlation between mRNA levels and functional role of {alpha}1-adrenoceptor subtypes in arteries: evidence of {alpha}1L as a functional isoform of the {alpha}1A-adrenoceptor Am J Physiol Heart Circ Physiol, November 1, 2005; 289(5): H1923 - H1932. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |